- Feb 28, 2016
- Rhode Island
Lp(a) is genetic and doesn’t budge for much. Mine, you may remember, is 13 times normal, triple the “extremely high risk” level.Hey noctrune, welcome back.
How's your Lp(a) doing? I have read and heard some positive things about options for actually dealing with that.
Have you had valve surgery yet? You'll be pleased to know I decided to go of antibiotics near the end of last year. So after 10 years lets see if I am cured of that bacteria or I go in for another round of tough love.
I hope you continue to post in your happy bouyant and positive ways or yore.
PS have you read of these things? (I expect you're well aware by now)
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolGuidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain ...www.ncbi.nlm.nih.gov
Among patients with coronary heart disease receiving moderate to intensive statin therapy (eg, simvastatin 40–80 mg/d or atorvastatin 80 mg/d), approximately 50% to 60% achieve LDL-C levels <70 mg/dL (2,5). Of these, approximately 30% have LDL-C levels of 60 to 70 mg/dL (5). Whether patients with LDL-C levels close to 70 mg/dL on statin treatment derive incremental benefit from further lipid-lowering therapy is therefore a question that is frequently encountered in clinical practice.
Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) produce large reductions of LDL-C as monotherapy or when added to statins. An additional effect of PCSK9 inhibitors is to reduce lipoprotein(a) concentration by 20% to 25% (3,4). Lipoprotein(a) is a type of low-density lipoprotein particle whose concentration is determined primarily genetically. It is believed to have atherogenic, proinflammatory, and prothrombotic properties (6). Epidemiologic and genetic studies associate lipoprotein(a) concentration with the risk for incident coronary, peripheral artery, and cerebrovascular disease (7–9).
Yeah, meds that lower it are “right around the corner” - just like they have been for the last decade or so. I’ll believe it when I’m on them. I was, for what it’s worth, recently sought out by a company that is trying to get them past the FDA for an interview, as I was on a list of people with astronomically high Lp(a) levels. Not that I qualify to participate in their trials; no heart attack, no trial. The interviewer appreciated the irony of someone hoping for a mild heart attack so they could get in on a trial of their life saving med. Quite the knee slapper, eh?
Progressed to moderate stenosis this year. No replacement yet. Taking a sabbatical next year to travel with my wife; not seeing the point in working straight through to a retirement I may not live to enjoy.
Good luck with your bacteria.